You are here

iptacopan

EHA 2023 – Astrazeneca keeps up its complement defense

EHA 2023 – Astrazeneca keeps up its complement defense

EP Vantage

Flag link:

Novartis’s iptacopan meets primary endpoint in Phase III PNH trial

Novartis’s iptacopan meets primary endpoint in Phase III PNH trial

Clinical Trials Arena

clinical trials

Flag link:

Could This Be Novartis' Next Blockbuster Medicine?

Could This Be Novartis' Next Blockbuster Medicine?

Motley Fool

Flag link:

ASH: Novartis says rare disease med 'stands on its own,' diving deeper into head-to-head win against AstraZeneca

ASH: Novartis says rare disease med 'stands on its own,' diving deeper into head-to-head win against AstraZeneca

Fierce Biotech

Flag link:

Novartis' iptacopan meets PhIII test in fight against rare blood disease

Novartis' iptacopan meets PhIII test in fight against rare blood disease

Endpoints

clinical trials

paroxysmal nocturnal hemoglobinuria

Flag link:

Novartis, eyeing $3B market, beats AstraZeneca blood disorder blockbusters in phase 3

Novartis, eyeing $3B market, beats AstraZeneca blood disorder blockbusters in phase 3

Fierce Biotech

clinical trials

Flag link:

Novartis’ oral drug iptacopan tops injectables in head-to-head PNH trial

Novartis’ oral drug iptacopan tops injectables in head-to-head PNH trial

Pharmaphorum

clinical trials

Flag link:

Novartis’ iptacopan hits the mark in rare kidney disease C3G

Novartis’ iptacopan hits the mark in rare kidney disease C3G

Pharmaforum

Flag link:

EHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNH

EHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNH

Pharmaforum

clinical trials

Flag link:

Novartis' Most Advanced Kidney Compound Shows Promise in C3G

Novartis' Most Advanced Kidney Compound Shows Promise in C3G

BioSpace

clinical trials

Flag link: